Ceftazidime-avibactam plus aztreonam for extensively drug-resistant gram-negative infections in critically ill patients
Authors' conclusion
Ceftazidime-avibactam plus aztreonam combination demonstrated significant in vitro synergy against XDR pathogens with promising trends toward improved clinical outcomes in critically ill patients
Study context
- Population
- Critically ill adult ICU patients with confirmed XDR gram-negative infections, October 2024 to April 2025
- Participants
- 24 patients
- Exposure
- Synergy-positive vs synergy-negative cases
- Outcome
- Clinical response, microbiological clearance and 30-day mortality
Main finding
As reported in the abstract
Clinical improvement
P = 0.631
Observational data: associations, not effects.
Further findings
Microbiological clearance · achieved exclusively in synergy-positive cases
P = 0.534
Predictor of mortality: septic shock presentation
| OR (95 % CI) | P value | ||
|---|---|---|---|
| Septic shock presentation | 3.5 (0.7–17.8) | P = 0.134 | |
| 0.050.21520Odds ratio (log scale) |
In vitro synergy of ceftazidime-avibactam (CZA) with aztreonam (ATM)
- Synergy demonstrated (15/24)
- 62.5 %
- MIC with synergy, median (IQR 0.25-1.0)
- 0.5 μg/mL
- NDM (22/24)
- 91.7 %
- NDM + OXA-48 co-production (16/24)
- 66.7 %
Original publication
Ceftazidime-avibactam plus aztreonam for extensively drug-resistant gram-negative infections in critically ill patients. J Crit Care. Published 29 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →